Weifang Medical University, Weifang, PR China.
Department of Radiotherapy, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, PR China.
Future Oncol. 2018 Oct;14(25):2643-2650. doi: 10.2217/fon-2018-0285. Epub 2018 May 11.
We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer.
MATERIALS & METHODS: The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.
Kaplan-Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0.001) and poorer overall survival (p < 0.001). Multivariable Cox analysis further revealed SII as an independent prognostic factor for overall survival (p = 0.010) and progression-free survival (p = 0.001).
SII can serve as a useful biomarker to predict recurrence and death for patients with advanced non-small-cell lung cancer.
本研究旨在探讨系统免疫炎症指数（SII）与晚期非小细胞肺癌患者临床结局之间的关系。
SII 计算方法为血小板（P）×中性粒细胞（N）/淋巴细胞（L），数据在治疗前 1 周内获得。采用 Kaplan-Meier 分析和 Cox 比例风险模型评估 SII 的预后价值。
Kaplan-Meier 分析显示，SII 较高组的无进展生存期（p<0.001）和总生存期（p<0.001）更差。多变量 Cox 分析进一步表明 SII 是总生存期（p=0.010）和无进展生存期（p=0.001）的独立预后因素。
SII 可作为预测晚期非小细胞肺癌患者复发和死亡的有用生物标志物。
